Synthesis of a Novel Multifunctional Hybrid Drug as a Chemotherapeutic Treatment for Prostate Cancer
Sorensen, Kathleen M.
MetadataShow full item record
An estimated 1 in 7 men will be diagnosed with prostate cancer, the second most common cancer among men within their lifetime. Currently, the chemotherapeutic treatments for prostate cancer have proven to be effective for a certain amount of time before the disease progresses to Castrate Resistant Prostate Cancer (CRPC) where the treatments are no longer as effective. In order to target prostate cancer before and after CRPC, a novel multifunctional hybrid drug is synthesized to test its abilities to block the androgen receptor (AR) to stop the proliferation of prostate cancer cells. Two cancer combating molecules were specifically chosen to be synthesized together due to their functionality and similar functional groups: enzalutamide and sulforaphane. Enzalutamide, a secondary antiandrogen, is a current chemotherapeutic drug administered to CRPC patients. Sulforaphane is a isothiocyanate found in cruciferous plants that demonstrates anticancer properties such as inhibiting cancer cell growth and induced cancer cell death. In this study, using thin layer chromatography and 1H NMR, a novel chemotherapeutic product, (s)-(1-(((6-(5-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)pyridine-2-yl)hexyl)carbamothioyl)thio)-3-oxobutan-2-yl)carbamic acid, was successfully synthesized as a potential anti-prostate cancer drug.